This patent gives Neurosom the unique claim to register fluid content, extracellular space, and glymphatic clearance of waste in the brain through impedance measures. “This patent is another significant milestone for Neurosom™,” says CEO Viral Sheth. “We are developing the Sleep WISP™ to be both a sophisticated diagnostic and therapeutic tool in the next generation of brain care.”

LSI USA '26 will take place March 16-20 in Dana Point, CA. Reach out through the app or onsite to connect and learn more about how Neurosom is changing the future of brain care and dementia prevention.

"Emerging Neurotechnological Approaches to Management of Sleep Disturbances in Parkinson's Disease," in Clinical Parkinsonism and Related Disorders. Lead author, Mason Dallegge, a scientist at the Ichan School of Medicine, Mount Sinai Department of Neuroscience, and Dr. Allison C. Waters, PhD, Assistant Professor of Psychiatry and Neuroscience at the Nash Family Center for Advanced Circuit Therapeutics at the Ichan School of Medicine at Mount Sinai, led a team of medical professionals and scientists from Mount Sinai, along with Dr. Don Tucker, founder and Senior Scientist of Neurosom, to write an innovative paper on newfound ways to manage sleep disturbances in Parkinson's Disease (PD) through neurotechnology and neuromodulation.

The round was led by Portland Seed Fund’s Intrepid Oregon Fund, with participation from the Loomis Family Trust, OEN Angel Syndicate, and ONAMI, positioning the company to accelerate clinical progress and product development as it advances toward a priced Seed Round in the first half of 2026.

With recent FDA clearance of NEAT™, expanding clinical collaborations, and continued development of our Sleep WISP™ platform, 2026 is shaping up to be a pivotal year for Neurosom™.

Deep sleep, in particular, plays a critical role in physical recovery, brain health, and overall resilience. This well-written article breaks down how aging affects our sleep architecture, what each sleep stage means for the body’s recovery process, and practical ways to support more restorative nights.
Worth a read if you care about long-term health and performance.

This will be a fantastic opportunity to build on our fundraising and networking momentum of 2025, and to share our vision of better sleep and dementia prevention with a powerful community. Feel free to contact Viral through the bio partnering app if you would like to set up a meeting or learn more about Neurosom's mission to optimize sleep and promote brain health.

Gamma-band synchronization, a form of brain activity, is important for everyday cognitive function and memory, yet we all tend to lose this functionality as we age. In this study by French scientists, some elderly individuals successfully trained their minds through neurofeedback, achieving Gamma-band synchronization. However, the level of success varies based on individual neural dynamics.

We started our journey with this program in April of this year, and we are so grateful for the mentorship, network, and guidance this fine community of Oregon Leaders has given us over the year. Cara Turano, Yalda Moshiri, Rylee O'Brien, and Sarah Norris, you've gone over and above for our company, and we can't wait to share our vision of better brain health with the rest of the world.

We are finalists for the Oregon Entrepreneurs Network Angel Oregon Life and BioScience program, and the winner will be announced tonight and receive a $100,000 investment check! Our CEO, Viral Sheth, will attend and present our vision for better brain health, and regional investors will have the opportunity to invest in the local Oregon companies.

As the winners of the 2025 Oregon Entrepreneurs Network Stage Award—recognizing the progress our team has made in advancing Neurosom™ technologies—we were also honored to participate in the Collaborative EDO PubTalk “Tap Into Capital,” where founders from across Oregon shared their latest innovations and growth stories. It was an energizing night for the region’s startup community and a great opportunity to showcase how our technology is reshaping the future of sleep health. Watch the full presentation

Researchers at Osaka Metropolitan University in Japan have published a new study where they found that the Alzheimer's drug Lecanemab removes amyloid plaques from the brain but does not restore the brain's ability to clear those plaques. The brain waste clearance system, or glymphatic clearance, as scientists have named it, is the critical function that removes the toxic waste of the brain, which causes neurodegenerative diseases such as Alzheimer's.

We’re excited to share that our CEO, Viral Sheth, fresh off his win of the Oregon Entrepreneurs NetworkDevelopment Stage Award, will be presenting at the Collaborative EDOPubTalks: Tap into Capital, this Thursday, 5-7 pm at Claim 52 Brewing in Eugene, OR.

Neurosom's CEO, Viral Sheth, accepted the Oregon Entrepreneurs Network Development Stage Award last Thursday night at the Hilton Hotel in Portland, Oregon. OEN has provided Neurosom™ with critical support and mentoring throughout 2025 as we advance our mission of personalized brain care, sleep therapy, and reduced dementia risk.

A new study published in Nature Neuroscience suggests that Alzheimer's disease disrupts the body's circadian rhythms, which in turn shut down genes that regulate proper brain function and the ability to clear the brain of waste and harmful materials, like amyloid plaques. Erik S. Musiek, MD, PhD, the Charlotte & Paul Hagemann Professor of Neurology at WashU Medicine, who led the study, finds hope in the new science.

Our CEO, Viral Sheth, will attend and says, "Thrilled to be named a finalist by OEN! At Neurosom, we’re working to redefine brain health and dementia prevention through sleep and personalized at-home neuromodulation. Recognition like this fuels our mission."

This incredible platform run by @Oregon Entrepreneur Network has given us much guidance this year in the form of regular workshop meetings with successful PNW CEOs, investors, and leaders in the business community, as well as opportunities to perfect our networking and pitching strategies. We have gained much insight and focus from this opportunity and have also enjoyed meeting this lovely group of supportive people. See OEN announcement: https://lnkd.in/gV5DAjtj

Rotem Falach, a PhD candidate in Professor Yuval Nir’s Lab at Tel Aviv University, will showcase how open-source analytics and HD EEG are advancing understanding of sleep-dependent memory consolidation and Alzheimer’s-related neurophysiology.

Register Here»

Neurosom sits at the intersection of brain health and digital therapeutics. With the Sleep WISP™, and our FDA-approved AI software, we can deliver clinical therapies for patients and, over time, wellness solutions for proactive brain care, making restorative sleep accessible at scale.

Every three seconds, someone in the world develops dementia. Current solutions fall short: medications sedate without restoring brain health, while consumer wearables only track sleep but don’t improve it.
Our Sleep WISP™ system is a simple, wearable headband that can be safely self-administered at home — but it does much more than track sleep. It monitors brain activity in real time using EEG.

As we approach the Bend Venture Conference on October 16 and 17, Neurosom™ is gearing up to share our mission to optimize sleep and reduce the risk of dementia. Our company was founded by neuroscientists who pioneered innovations in brain monitoring. Through studying the brain, scientists learned that deep sleep is essential for clearing toxic proteins from the brain through the glymphatic system, the brain’s waste removal pathway. When deep sleep is disrupted, glymphatic clearance fails, memory suffers, and neurodegeneration accelerates.